ATE509630T1 - Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern - Google Patents

Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern

Info

Publication number: ATE509630T1
Authority: AT; Austria
Prior art keywords: sup; atpase inhibitors; cancer treatment; pancreas cancer; provides
Prior art date: 2004-09-02

Application number

AT05794315T

Other languages

English (en)

Inventor

Mehran Khodadoust

Ajay Sharma

Original Assignee

Bionaut Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-02

Filing date

2005-09-02

Publication date

2011-06-15

2005-09-02 Application filed by Bionaut Pharmaceuticals Inc filed Critical Bionaut Pharmaceuticals Inc

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE509630T1 publication Critical patent/ATE509630T1/de

Links

206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 3
239000000362 adenosine triphosphatase inhibitor Substances 0.000 title abstract 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
208000008443 pancreatic carcinoma Diseases 0.000 title 1
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 abstract 1
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 abstract 1
MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 abstract 1
244000166550 Strophanthus gratus Species 0.000 abstract 1
229940097217 cardiac glycoside Drugs 0.000 abstract 1
239000002368 cardiac glycoside Substances 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960003343 ouabain Drugs 0.000 abstract 1
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229930190098 proscillaridin Natural products 0.000 abstract 1
229960003584 proscillaridin Drugs 0.000 abstract 1
MYEJFUXQJGHEQK-UHFFFAOYSA-N proscillaridin A Natural products OC1C(O)C(O)C(C)OC1OC1C=C2CCC3C4(O)CCC(C5=COC(=O)C=C5)C4(C)CCC3C2(C)CC1 MYEJFUXQJGHEQK-UHFFFAOYSA-N 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
229930002534 steroid glycoside Natural products 0.000 abstract 1
150000008143 steroidal glycosides Chemical class 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05794315T 2004-09-02 2005-09-02 Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern ATE509630T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60668404P	2004-09-02	2004-09-02
PCT/US2005/031331 WO2006028969A1 (en)	2004-09-02	2005-09-02	Pancreatic cancer treatment using na+/k+ atpase inhibitors

Publications (1)

Publication Number	Publication Date
ATE509630T1 true ATE509630T1 (de)	2011-06-15

Family

ID=35395786

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05794315T ATE509630T1 (de)	2004-09-02	2005-09-02	Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern

Country Status (4)

Country	Link
US (1)	US20060135442A1 (de)
EP (1)	EP1796688B1 (de)
AT (1)	ATE509630T1 (de)
WO (1)	WO2006028969A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080027010A1 (en) *	2004-09-02	2008-01-31	Bionaut Pharmaceuticals, Inc.	Treatment of refractory cancers using Na+/K+-ATPase inhibitors
EP1789090A2 (de) *	2004-09-02	2007-05-30	Bionaut Pharmaceuticals, Inc.	Kombinatorische chemotherapiebehandlung mit na+/k+-atpase-hemmern
US20060135468A1 (en) *	2004-09-02	2006-06-22	Bionaut Pharmaceuticals, Inc.	Treatment of refractory cancers using NA+/K+ ATPase inhibitors
WO2006044916A2 (en) *	2004-10-18	2006-04-27	Bionaut Pharmaceuticals, Inc.	Use of na+/ k+-atpase inhibitors and antagonists thereof
JP2009522383A (ja) *	2006-01-09	2009-06-11	ビーティージー・インターナショナル・リミテッド	低酸素誘導因子−１の調節物質及び関連する使用
EP2043651A2 (de) *	2006-07-05	2009-04-08	Exelixis, Inc.	Verfahren zur verwendung von igf1r und abl-kinase-modulatoren
US20110165291A1 (en) *	2008-11-12	2011-07-07	Andrew Loblaw	Nutritional supplement
US20110038852A1 (en) *	2009-06-10	2011-02-17	3-V Biosciences, Inc.	Antivirals that target transporters, carriers, and ion channels
US8921320B2 (en) *	2011-07-21	2014-12-30	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Targeted osmotic lysis of cancer cells
WO2016019062A1 (en) *	2014-07-29	2016-02-04	Alliance Of Cardiovascular Researchers	Priming of pancreatic tumors cells and cancer stem cells to trail-induced apoptosis
WO2023008533A1 (ja) *	2021-07-30	2023-02-02	国立研究開発法人科学技術振興機構	膵臓がん及び胆管がんの治療のための医薬用組成物
CN116999559A (zh) *	2022-04-28	2023-11-07	中山大学	硬脂酸或硬脂酰CoA去饱和酶抑制剂在制备抗肿瘤药物中的应用
CN118021828B (zh) *	2024-02-28	2024-08-30	上海陶术生物科技有限公司	化合物0449-0141作为ndm-1抑制剂在抗菌中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2464203A (en) *	1943-05-21	1949-03-15	Boots Pure Drug Co Ltd	Manufacture of dienoestrol
NL255279A (de) *	1959-08-27
US3079297A (en) *	1960-05-31	1963-02-26	Bayer Ag	Method of combating gastropods
SU557755A3 (ru) *	1968-08-19	1977-05-05	Янссен Фармасьютика Н.В. (Фирма)	Способ получени производных имидазола
US4022834A (en) *	1972-03-16	1977-05-10	A/S Farmaceutisk Industri	Antibacterially active hexamethylene-bis-biguanides
US4022962A (en) *	1975-02-03	1977-05-10	Cooper Laboratories, Inc.	Carbamylguanidine antimicrobial compounds
EP0100172B1 (de) *	1982-07-23	1987-08-12	Imperial Chemical Industries Plc	Amide-Derivate
PT84857B (pt) *	1986-05-13	1990-02-08	Huseyin Ziya Ozel	Processo para a preparacao de extractos de plantas da especie nerium e de composicoes farmaceuticas que os contem
US5872103A (en) *	1986-11-26	1999-02-16	Belletti; Dino A.	Prevention of mammary tumors by treatment with cardiac glycosides
US5188837A (en) *	1989-11-13	1993-02-23	Nova Pharmaceutical Corporation	Lipsopheres for controlled delivery of substances
US5874423A (en) *	1992-09-10	1999-02-23	Yissum Research Development Co. Of The Hebrew University Of Jerusalem	Digitalis-like compounds
US6773669B1 (en) *	1995-03-10	2004-08-10	Maxcyte, Inc.	Flow electroporation chamber and method
US5891855A (en) *	1996-02-12	1999-04-06	The Scripps Research Institute	Inhibitors of leaderless protein export
CA2191923C (en) *	1996-12-03	2000-10-24	Ji-Won Yoon	Portulaca oleracea and tumor cell growth
JP2002526452A (ja) *	1998-09-24	2002-08-20	オゼル・ファーマスーティカルズ・インコーポレイテッド	キョウチクトウ抽出物、その医薬組成物及びその調整方法
EP1151295A4 (de) *	1999-02-01	2005-03-30	Cytovia Inc	Verfahren zur identifizierung therapeutisch effektiver antineoplastischer substanzen mittels kultivierter zellen mit intakten zellmembranen und damit zusammenhängende produkte
CA2362917C (en) *	1999-02-12	2003-08-05	Compass Pharmaceuticals, Llc	Methods for anti-tumor therapy
US8883856B2 (en) *	2000-02-28	2014-11-11	John Jackson	Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
AU2001278987A1 (en) *	2000-07-21	2002-02-05	Althea Technologies, Inc.	A systematic approach to mechanism-of-response analyses
AU781168B2 (en) *	2001-01-26	2005-05-12	Pfizer Products Inc.	Method of treating certain cancers using an estrogen agonist/antagonist
WO2002087618A1 (en) *	2001-04-27	2002-11-07	Takeda Chemical Industries, Ltd.	Preventive/therapeutic method for cancer
WO2003099011A1 (en) *	2002-05-28	2003-12-04	Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
US7204982B2 (en) *	2002-07-02	2007-04-17	The Regents Of The University Of California	Compositions and methods for treatment and detection of multiple cancers
US20050182106A1 (en) *	2002-07-11	2005-08-18	Sankyo Company, Limited	Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US7332525B2 (en) *	2003-01-17	2008-02-19	Castle Erik P	Method of treatment of prostate cancer and composition for treatment thereof
AU2004222653C1 (en) *	2003-03-17	2010-10-07	Amo Groningen B.V.	New method
WO2004087121A2 (en) *	2003-03-28	2004-10-14	Azaya Therapeutics, Inc.	Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
GB2419529B (en) *	2003-07-17	2008-01-09	Cotherix Inc	Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20050250709A1 (en) *	2003-12-19	2005-11-10	Bionaut Pharmaceuticals	Anti-neoplastic agents, combination therapies and related methods
US7820702B2 (en) *	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) *	2004-02-04	2005-08-18	Nirschl Alexandra A.	Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US20060135468A1 (en) *	2004-09-02	2006-06-22	Bionaut Pharmaceuticals, Inc.	Treatment of refractory cancers using NA+/K+ ATPase inhibitors
EP1789090A2 (de) *	2004-09-02	2007-05-30	Bionaut Pharmaceuticals, Inc.	Kombinatorische chemotherapiebehandlung mit na+/k+-atpase-hemmern
US20070105790A1 (en) *	2004-09-02	2007-05-10	Bionaut Pharmaceuticals, Inc.	Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
WO2006044916A2 (en) *	2004-10-18	2006-04-27	Bionaut Pharmaceuticals, Inc.	Use of na+/ k+-atpase inhibitors and antagonists thereof
US20060205679A1 (en) *	2004-10-22	2006-09-14	Azaya Therapeutics, Inc.	Topical and oral formulations of cardiac glycosides for treating skin diseases
GB0613630D0 (en) *	2006-07-10	2006-08-16	Rolls Royce Plc	A seal arrangement

2005
- 2005-09-02 EP EP05794315A patent/EP1796688B1/de not_active Expired - Lifetime
- 2005-09-02 AT AT05794315T patent/ATE509630T1/de not_active IP Right Cessation
- 2005-09-02 WO PCT/US2005/031331 patent/WO2006028969A1/en not_active Ceased
- 2005-09-02 US US11/219,638 patent/US20060135442A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1796688A1 (de)	2007-06-20
US20060135442A1 (en)	2006-06-22
WO2006028969A1 (en)	2006-03-16
EP1796688B1 (de)	2011-05-18

Legal Events

Date	Code	Title	Description
2011-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
BRPI0607809A2 (pt)	2009-06-13	uso de uma composição compreendendo nanopartìculas, composição e kit
ATE509630T1 (de)	2011-06-15	Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
SG164368A1 (en)	2010-09-29	Treatment of cancer
WO2004018000A3 (en)	2004-09-02	Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
BRPI0622054B8 (pt)	2021-05-25	composto e composição farmacêutica
BRPI0612845A8 (pt)	2018-01-23	composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
WO2006044916A3 (en)	2007-01-04	Use of na+/ k+-atpase inhibitors and antagonists thereof
NO20062876L (no)	2006-08-08	Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
UA118645C2 (uk)	2019-02-25	Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
CR10147A (es)	2008-10-29	"ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
TW200612918A (en)	2006-05-01	Lonidamine analogs
WO2006029018A3 (en)	2006-05-11	Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
ATE444309T1 (de)	2009-10-15	Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
WO2008045228A3 (en)	2009-02-12	Medical devices having porous regions for controlled therapeutic agent exposure or delivery
CL2007002062A1 (es)	2008-01-18	Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
TW200716141A (en)	2007-05-01	Compositions and methods for treatment for neoplasms
CY1111263T1 (el)	2015-08-05	Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
WO2006029020A3 (en)	2006-06-01	Treatments of refractory cancers using na+/k+-atpase inhibitors
WO2005084296A3 (en)	2006-02-02	Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
AU2010266004A8 (en)	2014-12-18	Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
WO2004050033A3 (en)	2004-08-05	Method of treating cancers
WO2006015079A3 (en)	2006-06-29	Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
NO20024076L (no)	2002-08-27	Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer
UA88638C2 (ru)	2009-11-10	Бета-карболины, полезные для лечения воспалительного заболевания